Gerald Miletello
Hematology | Oncology
605 Medical Center Dr Ste B
Alexandria, LA 71301
Alexandria, LA 71301
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
A randomized trial of a multimodal lifestyle intervention in cancer survivors.
Journal: Frontiers in oncology
Published: August 08, 2025
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2.
Journal: Journal of investigative medicine : the official publication of the American Federation for Clinical Research
Published: February 05, 2021
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry.
Journal: Journal for immunotherapy of cancer
Published: December 05, 2018
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
Journal: Journal for immunotherapy of cancer
Published: October 31, 2018
Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma.
Journal: British journal of haematology
Published: June 23, 2017
Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.
Journal: Clinical genitourinary cancer
Published: March 25, 2016
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
Journal: Cancer immunology, immunotherapy : CII
Published: October 27, 2015
Showing 1-7 of 7
Last Updated: 09/26/2026